BNTX241220C77500
- 10.72
- 0.000.00%
BioNTech Newsroom
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $154.43
BioNTech SE's Strategic and Clinical Advancements Drive Buy Rating on BNT327's Promise in Oncology
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating, Announces Target Price $122
J.P. Morgan Reaffirms Their Hold Rating on BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $149
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $149
BioNTech Analyst Ratings
Wells Fargo Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $170
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
BioNTech SE's Promising Future: Buy Rating Backed by Breakthrough Cancer Therapy and Expansive Pipeline
Strategic Combinations Propel BioNTech's B7-H3 ADC BNT324 Amidst Competitive Landscape: Analyst 'Buy' Rating
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
BioNTech SE (BNTX) Receives a Buy From Morgan Stanley
BMO Capital Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $126
Promising Oncology Developments and Stable COVID-19 Business Drive BioNTech SE's Buy Rating
CCORF Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $171.44
BioNTech Price Target Raised to $171.44/Share From $171.00 by Canaccord Genuity